These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23887074)

  • 21. Can FSH co-trigger prevent OHSS?
    Rosen MP; Meldrum DR
    Fertil Steril; 2012 Mar; 97(3):534-5. PubMed ID: 22285746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GnRHa to trigger final oocyte maturation: a time to reconsider.
    Humaidan P; Papanikolaou EG; Tarlatzis BC
    Hum Reprod; 2009 Oct; 24(10):2389-94. PubMed ID: 19608565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.
    Griffin D; Benadiva C; Kummer N; Budinetz T; Nulsen J; Engmann L
    Fertil Steril; 2012 Jun; 97(6):1316-20. PubMed ID: 22480822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro oocyte maturation for safer treatment of infertility. The risk of ovarian overstimulation syndrome is minimized].
    Hreinsson J; Fridström M
    Lakartidningen; 2004 Nov; 101(46):3665-8, 3671. PubMed ID: 15586490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro fertilization in the polycystic ovary syndrome patient: an update.
    Lin K; Coutifaris C
    Clin Obstet Gynecol; 2007 Mar; 50(1):268-76. PubMed ID: 17304041
    [No Abstract]   [Full Text] [Related]  

  • 27. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction.
    Cerrillo M; Rodríguez S; Mayoral M; Pacheco A; Martínez-Salazar J; Garcia-Velasco JA
    Fertil Steril; 2009 Apr; 91(4 Suppl):1526-8. PubMed ID: 18990367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GnRHa to trigger final oocyte maturation: a time to reconsider.
    Youssef M; van der Veen F; van Wely M
    Hum Reprod; 2010 Feb; 25(2):559. PubMed ID: 19955105
    [No Abstract]   [Full Text] [Related]  

  • 29. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exposure to human chorionic gonadotropin during in vitro maturation does not improve the maturation rate and developmental potential of immature oocytes from patients with polycystic ovary syndrome.
    Ge HS; Huang XF; Zhang W; Zhao JZ; Lin JJ; Zhou W
    Fertil Steril; 2008 Jan; 89(1):98-103. PubMed ID: 17524398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem.
    Huber M; Hadziosmanovic N; Berglund L; Holte J
    Fertil Steril; 2013 Nov; 100(5):1270-6. PubMed ID: 23931964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
    Griesinger G
    Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian hyperstimulation syndrome prevention strategies: Luteal support strategies to optimize pregnancy success in cycles with gonadotropin-releasing hormone agonist ovulatory trigger.
    Engmann L; Benadiva C
    Semin Reprod Med; 2010 Nov; 28(6):506-12. PubMed ID: 21082510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization.
    Fridén BE; Nilsson L
    Acta Obstet Gynecol Scand; 2005 Aug; 84(8):812-6. PubMed ID: 16026411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analogues agonists and antagonists: what is their role outside of fertilization in vitro?].
    Antoine JM; Merviel P; Alvarez S; Mandelbaum J; Salat-Baroux J; Uzan S
    Gynecol Obstet Fertil; 2000 Oct; 28(10):757-9. PubMed ID: 11244639
    [No Abstract]   [Full Text] [Related]  

  • 37. Estrogen-suppressed in vitro maturation: a novel approach to in vitro maturation.
    Vitek WS; Witmyer J; Carson SA; Robins JC
    Fertil Steril; 2013 Jun; 99(7):1886-90. PubMed ID: 23517862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol.
    Chen SL; Ye DS; Chen X; Yang XH; Zheng HY; Tang Y; He YX; Guo W
    Hum Reprod; 2012 May; 27(5):1351-6. PubMed ID: 22419746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?
    Fauser BC; Devroey P
    Fertil Steril; 2005 Jun; 83(6):1607-11. PubMed ID: 15950626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coasting. A viable option for patients at risk of ovarian hyperstimulation syndrome.
    Gafar AH; Abotalib ZM
    Saudi Med J; 2002 Nov; 23(11):1398-401. PubMed ID: 12506304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.